Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shaftesbury Capital hails West End potential with bullish outlook

(Sharecast News) - West End-focused real estate investment trust Shaftesbury Capital delivered a confident outlook on Thursday, hailing strong leasing momentum and occupancy levels since the start of the year. The company has signed 128 leasing transactions so far in 2025, representing £11.3m of new contracted rent at 8% ahead of estimated rental values at the year-end.

The first five months of the year have seen several new openings across the portfolio, including Nespresso, Dolce & Gabbana, Autry and Farm Rio.

Annualised rent roll has risen 3% on a like-for-like basis to £210m since the start of the year, while occupancy levels remain high with just 1.7% of ERV available to let, compared with 2.6% in December.

Shaftesbury chief executive Ian Hawksworth said clients were seeing "positive trends in footfall and sales" so far this year. "Customers recognise the exceptional features of London's West End with broad appeal to domestic and international businesses and visitors," he said.

The first quarter saw Shaftesbury sell a 25% stake in its £2.7bn Covent Garden estate to Norwegian sovereign wealth fund, Norges Bank Investment Management, raising cash proceeds of £570m.

In an AGM trading update on Thursday, the company said the deal provides it with "significant optionality" and sees a "range of options to deploy the proceeds including acquisitions, asset management and repositioning opportunities and repayment of outstanding debt".

The stock was more or less flat at 144p by 0935 BST, having jumped around 15% so far this year.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.